AbbVie Settles Adalimumab Biosimilar Dispute With Fresenius Kabi.

October 19, 2018

Reuters (10/18, Babu) reports AbbVie said Thursday that it settled its patent dispute with Fresenius Kabi Oncology Ltd regarding its Humira (adalimumab) biosimilar. As part of the settlement, AbbVie will grant Fresenius Kabi non-exclusive marketing right...